Atosiban Peptide: Tractocile, Oxytocin Antagonist Tocolytic for Preterm Labor
Atosiban (Tractocile) peptide guide covering oxytocin and vasopressin receptor antagonism, EU tocolytic approval, dosing from the label, half-life and safety limits.
Atosiban is a peptide drug with a tightly defined clinical purpose. It is a synthetic analog of oxytocin that acts as a competitive antagonist at the oxytocin receptor, and it is marketed in the European Union under the brand name Tractocile (and as generic atosiban products) for the short-term delay of preterm birth. Unlike many research-market peptides, atosiban has an approved regulatory label, a defined intravenous regimen and a documented safety record.
The framing that matters is "tocolytic for a narrow window." Atosiban is not a general hormone modulator and not a wellness compound. It is an inpatient, intravenous medicine given for a maximum of 48 hours to buy time in selected preterm labor cases, and its evidence and limits should be read in that context.
This guide is educational and not medical advice. Atosiban is a prescription, hospital-administered medicine for pregnancy. It should be started, monitored, changed or stopped only through qualified obstetric care.
For related context, compare this guide with oxytocin, the natural agonist whose action atosiban blocks; icatibant, another receptor- antagonist peptide drug; and octreotide, an approved peptide that works through a very different receptor family. The basics in what peptides are and the peptide half-life guide also help explain why atosiban is dosed the way it is.
Atosiban At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic nonapeptide oxytocin analog that antagonizes oxytocin and vasopressin V1a receptors. |
| Brand names | Tractocile (originator) and several generic atosiban products in the EU. |
| Main effect | Reduces oxytocin-driven uterine contractions by blocking the myometrial oxytocin receptor. |
| Approval status | Approved in the European Union as a tocolytic; not approved by the US FDA. |
| Route | Intravenous only: bolus, then high-rate infusion, then maintenance infusion. |
| Evidence type | EMA label, pharmacokinetic studies and randomized controlled trials versus beta-agonists. |
| Main safety frame | Short-duration use, gestational-age limits and contraindications tied to pregnancy complications. |
How An Oxytocin Antagonist Slows Contractions
Oxytocin is a key driver of uterine contractions. It acts through the oxytocin receptor, a G-protein-coupled receptor in the myometrium that signals mainly through the Gq/phospholipase C pathway. Activation raises intracellular calcium and increases prostaglandin production, and both effects promote coordinated uterine contraction. Oxytocin receptor density in the uterus rises toward term, which is part of why oxytocin signaling becomes so important in labor.
Atosiban is a competitive antagonist at that receptor. By occupying the oxytocin binding site without fully activating downstream signaling, it reduces the calcium and prostaglandin response that oxytocin would otherwise produce. The intended result is fewer and weaker contractions.
Atosiban is not perfectly selective. Published pharmacology describes meaningful affinity for vasopressin receptors, particularly the V1a subtype, in addition to the oxytocin receptor. That dual activity is one reason newer, more oxytocin-selective antagonists such as retosiban, barusiban and nolasiban were investigated as potential successors. Atosiban remains the only oxytocin receptor antagonist that reached the market as a tocolytic.
Approval, Origin And Dosing Context
Atosiban was developed by Ferring Pharmaceuticals and received European marketing authorization for Tractocile in January 2000. It is indicated to delay imminent preterm birth in pregnant women with regular uterine contractions, cervical change and a gestational age in roughly the 24 to 33 week range, when the pregnancy is otherwise uncomplicated.
The label dosing is given in three steps and is described here only to explain how the drug is used. These figures are label references, not a recommendation to self-administer anything.
| Step | What the label describes | Purpose |
|---|---|---|
| Initial bolus | 6.75 mg given intravenously over about one minute. | Rapid receptor occupancy. |
| Loading infusion | A high-rate infusion (300 micrograms per minute) for 3 hours. | Establish and hold effect. |
| Maintenance infusion | A lower-rate infusion (100 micrograms per minute) for up to 45 more hours. | Sustain suppression. |
Total treatment is limited to a maximum of 48 hours, and the label caps the cumulative dose. The short ceiling is deliberate. Atosiban is meant to delay delivery long enough to give antenatal corticosteroids time to act and to allow transfer to an appropriate facility, not to maintain a pregnancy indefinitely.
The pharmacokinetics fit that design. After the infusion, plasma concentrations fall biexponentially, with an initial half-life of roughly 0.2 hours and a terminal half-life near 1.7 hours in pharmacokinetic studies of pregnant women with preterm contractions. Steady-state plasma concentrations are reached within about an hour of starting the infusion. A short half-life makes the effect easy to titrate and to stop, which is useful for an inpatient infusion drug.
What The Evidence Shows, And Its Limits
The clearest evidence for atosiban is comparative. Randomized controlled trials compared atosiban with beta-adrenergic agonists such as salbutamol, ritodrine and terbutaline. In a double-blind, randomized comparison with salbutamol in women in preterm labor at 23 to 33 weeks, atosiban achieved similar success in delaying delivery while being better tolerated, with fewer maternal cardiovascular adverse effects. Across the broader trial program, atosiban's headline message has been consistent: roughly comparable tocolytic efficacy to beta-agonists, but a more favorable maternal side-effect profile.
The honest limit is harder. The evidence that atosiban improves the outcomes that matter most, meaning neonatal death, serious neonatal morbidity or long-term infant health, is not strong. Tocolytics in general have a modest, short-term role: they can delay delivery by a day or two, which is valuable for giving steroids and arranging transfer, but they have not been shown to dramatically change the most important neonatal outcomes. Atosiban's main selling point over older agents is tolerability, not a demonstrated leap in infant survival.
The United States history underscores the caution. Atosiban was studied in a US placebo-controlled trial, but it was not approved by the FDA. Regulatory concern focused in part on an imbalance in adverse fetal and neonatal outcomes, particularly in the lowest gestational-age strata where some patients may have been enrolled below the gestational ages later targeted by the EU label. The practical reading is that gestational-age selection and avoiding inappropriate candidates are part of using the drug safely, and that "approved in Europe" does not mean "approved everywhere."
Safety Limits
Atosiban's tolerability advantage over beta-agonists is real, but it is still a drug used in a high-stakes setting. The label defines who should not receive it and what to watch for.
| Safety issue | Why it matters |
|---|---|
| Gestational-age window | Use is defined for a specific range (about 24 to 33 weeks); use outside it is not supported by the label. |
| Contraindicating pregnancy conditions | Abnormal placentation, placental abruption, intrauterine fetal death, eclampsia or severe pre-eclampsia, and conditions where continuing the pregnancy is dangerous are contraindications. |
| Common adverse events | Nausea is the most frequently reported; headache, dizziness, hot flushes, vomiting, tachycardia and injection-site reactions also occur. |
| Maternal monitoring | Uterine bleeding and uterine atony should be monitored, and the amount of blood loss after delivery watched. |
| Multiple pregnancy and cardiovascular setting | Limited data in multiple pregnancy and certain cardiovascular contexts call for caution. |
| Not a home medicine | Atosiban is an intravenous, supervised hospital treatment, not a self-administered injectable. |
Because atosiban is intravenous and short-course, its risk profile is dominated by the obstetric situation rather than by chronic-exposure toxicity. That is the opposite of how many long-term peptide therapies are evaluated.
How To Evaluate An Atosiban Claim
Atosiban occasionally appears in peptide discussions far outside obstetrics. A few questions separate accurate information from noise.
First, does the source acknowledge that atosiban is intravenous, hospital- administered and limited to a 48-hour course? Any framing as a casual injectable is wrong.
Second, does it state the approval reality honestly: approved in the EU as Tractocile, not approved by the FDA? An "approved tocolytic" claim without that nuance is incomplete.
Third, does it distinguish efficacy from outcomes? Atosiban can delay delivery comparably to beta-agonists with better tolerability, but that is not the same as proven improvement in neonatal survival.
Fourth, does it respect the contraindications? Tocolysis is wrong when delivery is actually the safer choice, such as in abruption or intrauterine infection.
Fifth, is the source using an obstetric, supervised, gestational-age-restricted indication to imply some unrelated "anti-oxytocin" use? That is a red flag, much as it would be for any oxytocin-axis claim.
Bottom Line
Atosiban is a genuine, approved peptide medicine with a narrow and well-defined job. As a competitive oxytocin (and vasopressin V1a) receptor antagonist, it reduces oxytocin-driven uterine contractions, and the EU label supports its use as a short-term, intravenous tocolytic to delay imminent preterm birth in selected, uncomplicated cases.
Its strengths are clarity and tolerability: a defined three-step infusion, a short half-life that makes the effect easy to control, and randomized evidence that it matches beta-agonists on delay while causing fewer maternal cardiovascular side effects. Its limits are equally clear: it is not FDA- approved, the evidence for improving the hardest neonatal outcomes is modest, and it is bound by strict gestational-age limits and pregnancy-specific contraindications. Atosiban is best understood as a focused obstetric tool, not a general oxytocin-system peptide for any other purpose.
References
European Medicines Agency. Tractocile (atosiban) Summary of Product Characteristics.
European Medicines Agency. Tractocile EPAR Scientific Discussion.
European Medicines Agency. Atosiban SUN (generic atosiban) Summary of Product Characteristics.
Goodwin TM, et al. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. Am J Obstet Gynecol. 1995.
Goodwin TM, et al. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstet Gynecol. 1996.
The Worldwide Atosiban versus Beta-agonists Study Group. Treatment of preterm labour with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol. Eur J Obstet Gynecol Reprod Biol. 2001.
Romero R, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol. 2000.
Arrowsmith S, Wray S. Oxytocin: its mechanism of action and receptor signalling in the myometrium. J Neuroendocrinol.
Kim SH, et al. Oxytocin receptor antagonists, atosiban and nolasiban, inhibit prostaglandin F2alpha-induced contractions and inflammatory responses in human myometrium. Sci Rep.
GlaxoSmithKline. A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour. ClinicalTrials.gov NCT02292771.